Arialys Therapeutics, a clinical-stage biotechnology company pioneering new precision medicines for autoimmune neuropsychiatry, announced the appointment of Sankalp “Sam” Gokhale, M.D., as Chief Medical Officer. Dr. Gokhale is a U.S. board-certified neurologist with over 15 years of clinical practice and pharmaceutical industry experience. He has extensive expertise in all phases of clinical development, specifically in rare disease neurology indications.
“I am delighted to welcome Sam to the team. As a board-certified neurologist specializing in neurological critical care and a clinical trialist focused on rare, autoimmune neurology diseases, Sam brings a wealth of experience to Arialys,” said Peter Flynn, Ph.D., President and CEO of Arialys Therapeutics. “Sam joins us on our transition to a clinical-stage company, and his extensive experience running global clinical studies at all stages of development, and interacting with regulatory authorities, will be vital as we pursue clinical proof-of-concept for our lead therapeutic candidate, ART5803.”
“I am excited to join the Arialys team and help drive the development of ART5803, a first-in-class precision medicine for the treatment of autoimmune neuropsychiatric disease,” said Dr. Gokhale. “There are currently no approved therapies for anti-NMDA receptor encephalitis, and emerging but compelling data suggest that autoantibodies are a component of broader psychosis indications such as schizophrenia, schizoaffective disorder, as well as dementia.”
Also Read: Molecular Partners and Orano Med Expand 212Pb-DARPin Partnership
Dr. Gokhale brings experience in building clinical development and medical functions, extensive interactions with global regulatory authorities in the rare auto-immune neurology space, and robust networks of global key opinion leaders. He most recently served as Senior Vice President, Head of Clinical Development at Dianthus Therapeutics, where he led global clinical studies assessing a therapeutic monoclonal antibody in myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Prior to Dianthus, Sam held roles in clinical development with progressively increasing responsibilities at Radius Health, leading the clinical development of oral CBD for multiple rare neuropsychiatric and epilepsy indications; and at Alexion Pharmaceuticals, leading multiple Phase 2 and 3 global clinical trials (pediatric and adult) for eculizumab and ravulizumab in myasthenia gravis, with U.S. FDA approval of ravulizumab in myasthenia gravis.
After attending medical school in Mumbai, India, Dr. Gokhale completed his neurology residency at Beth Israel Deaconess Medical Center / Boston Children’s Hospital at Harvard Medical School and a fellowship in neurological critical care at Duke University Medical Center and received his M.B.A. from the University of Arizona. Dr. Gokhale was instrumental in building the successful neurocritical care program at the Banner – University Medical Center in Tucson, Arizona prior to transitioning to the biopharmaceutical industry.
SOURCE: Businesswire